Difference between revisions of "Part:BBa K2549005"
Line 3: | Line 3: | ||
<partinfo>BBa_K2549005 short</partinfo> | <partinfo>BBa_K2549005 short</partinfo> | ||
− | Anti-CD19(αCD19) is a CD19 scFv. Its heavy-chain variable region(αCD19a) and light-chain variable region(αCD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S) | + | Anti-CD19 (αCD19) is a CD19 scFv. Its heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S for short)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19 (surCD19 was used in our project, [[Part:BBa K2549005]]). |
− | |||
− | |||
− | |||
− | |||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo> | <partinfo>BBa_K2549005 SequenceAndFeatures</partinfo> | ||
− | === | + | |
− | + | <!-- Add more about the biology of this part here --> | |
+ | ===Usage and Biology=== | ||
+ | TBA | ||
+ | |||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
===Functional Parameters=== | ===Functional Parameters=== | ||
<partinfo>BBa_K2549005 parameters</partinfo> | <partinfo>BBa_K2549005 parameters</partinfo> | ||
− | + | --> | |
+ | |||
+ | |||
+ | ===References=== |
Revision as of 03:03, 7 October 2018
anti-CD19
Anti-CD19 (αCD19) is a CD19 scFv. Its heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) are fused using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S for short)[1]. It was used as the extracellular domain of the SynNotch, thus accomplishing the contact-dependent signal input against CD19 (surCD19 was used in our project, Part:BBa K2549005).
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 444
Usage and Biology
TBA
References
- ↑ Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005